The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
cSCC is one of the most common cancers in the U.S. and globally
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
The submission is supported by results from the Phase 3b APEX study
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Subscribe To Our Newsletter & Stay Updated
